

## Product Data Sheet

Product Name: lbiglustat

Cat. No.: GC19196

### Chemical Properties

Cas. No. 1401090-53-6

SMILES O=C(O[C@@H]1CN2CCC1CC2)NC(C)(C3=CSC(C4=CC=C(F)C=C4)=N3)C


Formula  $C_{20}H_{24}FN_3O_2S$  M.Wt 389.49

Solubility DMSO :  $\geq 75$  mg/mL (192.56 mM) Storage Store at  $-20^{\circ}C$

General tips For obtaining a higher solubility , please warm the tube at  $37^{\circ}C$  and shake it in the ultrasonic bath for a while. Stock solution can be stored below  $-20^{\circ}C$  for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



### Background

lbiglustat is an inhibitor of glucosylceramide synthase extracted from patent WO 2015089067 A1, compound example 64.

lbiglustat is in phase II clinical trials for the treatment of Fabry's disease. Fabry disease, an X-linked disorder of glycosphingolipids that is caused by mutations of the GLA gene that codes for  $\alpha$ -galactosidase A, leads to dysfunction of many cell types and includes a systemic vasculopathy[2]. Substrate reduction therapy is an approach that reduces the synthesis of lipids reaching the lysosome through inhibition of glucosylceramide synthase (GCS)[1].

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

## Product Data Sheet

---

References:

[1]. WO 2015089067 A1

[2]. Schiffmann R, et al. Fabry disease. Handb Clin Neurol. 2015;132:231-48.

***Caution: Product has not been fully validated for medical applications. For research use only.***

***Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: [tech@glpbio.com](mailto:tech@glpbio.com)***

***Address: 10292 Central Ave. #205, Montclair, CA, USA***